Traditional CROs fragment device development with costly hand-offs and learning curves. Veranex unites the essential disciplines for medical device & diagnostic development under one roof from sketch to evidence-generation to market launch.
All connected. All aligned. All accelerating your path to market—delivering breakthrough devices and diagnostics that improve patient lives sooner.
Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.
Purpose-built solutions. Proven results. User & Patient-centered innovation.
Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity. Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.
We are the Innovation CRO.
Legacy of excellence. Proven execution. Patient impact accelerated.
Study Co-Authored by Veranex Found that Mobile Cardiac Outpatient Telemetry (MCOT) was Associated with Lower Readmissions and Healthcare Costs in Post-Stroke Monitored Patients, Compared to Implantabl
This study compares the health and economic outcomes of using mobile cardiac outpatient telemetry (MCOT) and implantable loop recorders (ILRs) for long-term monitoring following an inpatient visit in patients who have had a stroke by analyzing Optum’s de-identified Clinformatics® Data Mart Database claims for hospital admissions between 2017 and 2020. MCOT was associated with decreased readmissions (p = 0.016), lower healthcare costs (p < 0.001) and a trend toward lower mortality in patients with stroke (p = 0.051), when compared with ILR monitoring.
